Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 27;16(4):e59177.
doi: 10.7759/cureus.59177. eCollection 2024 Apr.

Ophthalmic Manifestations of COVID-19: A Retrospective Study on Prevalence, Characteristics, and Clinical Implications

Affiliations

Ophthalmic Manifestations of COVID-19: A Retrospective Study on Prevalence, Characteristics, and Clinical Implications

Monika Patel et al. Cureus. .

Abstract

Background: The coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, has had far-reaching implications beyond the respiratory system. Mounting evidence suggests that COVID-19 can impact various organ systems, including the eyes. This study aimed to elucidate the prevalence, characteristics, and clinical implications of ophthalmic manifestations in patients diagnosed with COVID-19.

Methods: This retrospective study analyzed data from electronic medical records of adult patients hospitalized with COVID-19 between March 1, 2020, and December 31, 2020, at a large tertiary academic medical center. Ophthalmic manifestations, including conjunctivitis, dry eye symptoms, ocular pain, epiphora, ocular redness, and visual disturbances, were identified and examined for their prevalence, onset, duration, and associations with COVID-19 severity and systemic symptoms.

Results: Among 342 patients included in the study, 106 (31.0%) experienced at least one ophthalmic manifestation during their COVID-19 illness. Conjunctivitis was the most common manifestation in 62 patients (18.1%), followed by dry eye symptoms in 38 patients (11.1%), ocular pain/discomfort in 27 patients (7.9%), epiphora in 19 patients (5.6%), ocular redness in 14 patients (4.1%), and visual disturbances in nine patients (2.6%). Ophthalmic manifestations were significantly associated with severe COVID-19 illness (42.9% vs. 26.7%, p = 0.003) and the presence of systemic symptoms such as fever, cough, and dyspnea. The median time of onset was six days, and the median duration was 10 days.

Conclusions: Ophthalmic manifestations are prevalent in COVID-19 patients, particularly in those with severe illness and systemic symptoms. The study highlights the importance of recognizing and managing ocular symptoms in affected individuals and underscores the multifaceted nature of COVID-19, necessitating interdisciplinary collaboration for comprehensive patient care.

Keywords: covid-19 india; dry eye disorder; large data analysis. retrospective study design; ophthalmic manifestations; sars-cov-2; viral conjunctivitis.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Similar articles

References

    1. COVID-19 and eye: a review of ophthalmic manifestations of COVID-19. Sen M, Honavar SG, Sharma N, Sachdev MS. Indian J Ophthalmol. 2021;69:488–509. - PMC - PubMed
    1. Ocular manifestations of COVID-19. Al-Namaeh M. Ther Adv Ophthalmol. 2022;14:25158414221083374. - PMC - PubMed
    1. Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular Implications in humans and animals. Seah I, Agrawal R. Ocul Immunol Inflamm. 2020;28:391–395. - PMC - PubMed
    1. ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection. Zhou L, Xu Z, Castiglione GM, Soiberman US, Eberhart CG, Duh EJ. Ocul Surf. 2020;18:537–544. - PMC - PubMed
    1. Expression of the SARS-CoV-2 receptor ACE2 in human retina and diabetes-implications for retinopathy. Zhou L, Xu Z, Guerra J, Rosenberg AZ, Fenaroli P, Eberhart CG, Duh EJ. Invest Ophthalmol Vis Sci. 2021;62:6. - PMC - PubMed

LinkOut - more resources